Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.70)
# 1,886
Out of 5,126 analysts
95
Total ratings
34.83%
Success rate
9.1%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XOMA XOMA Royalty | Initiates: Buy | $76 | $24.86 | +205.71% | 1 | Dec 9, 2025 | |
| SAVA Cassava Sciences | Initiates: Buy | $8 | $2.03 | +294.09% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.50 | +4,300.00% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.25 | +4,667.58% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $4.14 | +310.63% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $0.14 | +7,807.98% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $57.86 | -13.58% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.20 | +1,316.67% | 1 | Sep 30, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.06 | +1,220.75% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.49 | +2,590.76% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $15.22 | +182.52% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.84 | +271.90% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $0.81 | +827.99% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $3.77 | +297.88% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $6.19 | +513.89% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.73 | +5,417.24% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $6.69 | +647.38% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $4.29 | +4,562.00% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $15.17 | +117.61% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $23.47 | +70.43% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.04 | +3,457.69% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $8.20 | +290.24% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $7.57 | +917.17% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.83 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $64.52 | -22.50% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.53 | +496.75% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $15.50 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $11.23 | +131.52% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $272.74 | -89.73% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.13 | +16,469.20% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $9.16 | +129.26% | 2 | Jul 12, 2017 |
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $24.86
Upside: +205.71%
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $2.03
Upside: +294.09%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.50
Upside: +4,300.00%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.25
Upside: +4,667.58%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $4.14
Upside: +310.63%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $0.14
Upside: +7,807.98%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $57.86
Upside: -13.58%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.20
Upside: +1,316.67%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.06
Upside: +1,220.75%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.49
Upside: +2,590.76%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $15.22
Upside: +182.52%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $4.84
Upside: +271.90%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.81
Upside: +827.99%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $3.77
Upside: +297.88%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $6.19
Upside: +513.89%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.73
Upside: +5,417.24%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $6.69
Upside: +647.38%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $4.29
Upside: +4,562.00%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $15.17
Upside: +117.61%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $23.47
Upside: +70.43%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.04
Upside: +3,457.69%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $8.20
Upside: +290.24%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $7.57
Upside: +917.17%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.83
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $64.52
Upside: -22.50%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.53
Upside: +496.75%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $15.50
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $11.23
Upside: +131.52%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $272.74
Upside: -89.73%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.13
Upside: +16,469.20%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $9.16
Upside: +129.26%